PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Form 10-Q — Aug 6, 2026
Pacific Biosciences reported Q2 2026 revenue of $39.0 million, down 2% year over year, with a net loss of $44.7 million and EPS of $(0.14); first-half revenue was $76.2 million, down 1% from 2025. The 10-Q discloses a CEO transition: Mark Van Oene was appointed President and CEO and joined the board effective August 5, 2026, succeeding Christian Henry, who stepped down from the executive role but remains a director. On July 30, 2026, the board approved a restructuring that will cut roughly 40 employees, about 8% of the workforce, targeting a $30-40 million reduction in annualized operating expenses by the end of 2027, with approximately $2.0 million of pre-tax charges expected in Q3 2026.
Key figures
- Revenue
- 39007000
- Total Debt
- 644332000
- Revenue Yoy
- -2%
- Total Assets
- 751850000
- Cash Position
- 61003000
- Shares Outstanding
- 310830759
- H1 2026 revenue
- 76185000
- Q2 gross profit
- 12638000
- Vega units q2 2025
- 38
- Vega units q2 2026
- 26
- Revio units q2 2025
- 15
- Revio units q2 2026
- 20
- Cash investments total
- 236900000
- Asset sale net proceeds
- 48100000
- Gain on disposal h1 2026
- 45796000
- Asset sale gross proceeds
- 50000000
- Pgi settlement q2 payment
- 8000000
- Expected restructuring charges
- $2.0 million pre-tax in Q3 2026
- Annualized opex reduction target
- $30 million to $40 million by end of 2027
- Restructuring workforce reduction
- approximately 40 employees (~8% of workforce)
Price after filing
Close on the filing date to close N calendar days later (from $1.17). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.